Souhaitez-vous accéder aux communiqués récents ?

ENA Respiratory Receives US$5m Investment from Flu Lab to Support Clinical Development of Novel Intranasal Antiviral Host Defence Immune Enhancer, INNA-051

Monaghan Medical was named Company of the Year by the Plattsburgh Chamber of Commerce for its contributions to the community and economy.

New York, United States, Nov. 11, 2024 (GLOBE NEWSWIRE) -- Researchers have used peptides to deliver drugs to target cells due to their remarkable efficacy and selectivity towards the different...

Austin, TX, USA, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Acute Respiratory Infection Market Size, Trends and Insights By Drug Type...

aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting

Monaghan Medical Corporation has been honored with the prestigious 2024 Zenith Award from the American Association for Respiratory Care (AARC). This award

aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal

Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following...

Approval follows EU approval of Dupixent for adults with COPD with raised blood eosinophils, and is based on two landmark Phase 3 trials showing Dupixent significantly reduced exacerbations, improved...

New US $3.13 million DOD contract extension to fund inclusion of younger adults in the ongoing Phase Ib study of INNA-051 nasal dry powder formulation and drug product optimization activities ...